• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dominari Q1 Revenue Increases by 395% Over Q1 2025

    5/13/26 7:00:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DOMH alert in real time by email

    Underwriting revenues increased over five-fold 

    NEW YORK, May 13, 2026 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) ("Dominari" or the "Company"), today announced highlights of its financial results for the quarter ended March 31, 2026, which were filed with the Securities and Exchange Commission ("SEC") in the Company's quarterly SEC Form 10Q.

    Dominari Holdings Inc. (PRNewsfoto/Dominari Holdings Inc.)

    The Company stated that:  "In  the first quarter of 2026,  we experienced continued revenue growth mainly from underwriting services, increased our annual recurring revenue from our management fees that we earn on deals that we bring to market  from essentially nil 18 months ago to over $1 million, and currently retain carried interest positions in some exciting emerging companies that we believe will yield positive returns over the  course of the next 24 months."  While the net income reflects one-time, non-recurring expenses for Q1 2026, we believe that the margins we expect from our core business for the balance of the year, will result in improved operating income and bottom-line performance."  The Company concluded, "the leadership team on our broker dealer subsidiary, led by Kyle Wool, continues to deliver world class investment banking services to our ever-growing list of clients, and we believe that will yield continued improved performance for the future."

    First Quarter 2026 Highlights

    • Revenue of $35.8 million, up 395% from the prior year's first quarter's revenue of $7.2 million.
      • Underwriting revenues totaled $32.9 million in Q1 2026 as compared to $5.6 million for Q1 2025, representing a 488% increase.
      • Carried interest totaled $1.1 million as compared to no such revenue in Q1 2025.
      • The Company's annual recurring revenue (ARR) increased to $1.1 million from $0.4 million at the end of Q1 2025, reflecting an increase of 189%.
    • Loss from operations of $37.6 million, an increase of $4.7 million compared to a loss of $32.9 million in the comparable period in 2025, reflecting increased one-time variable expenses in the quarter.
    • Other expense of $6.8 million as compared to other income of $0.4 million in Q1 2025. This book loss was primarily driven by the sale of the Company's strategic investment in American Bitcoin Corp. shares in January 2026 for $32.4 million in cash that were valued on the books at $39.4 million based upon the trading value of such shares at year end 2025. Note that the Company's investment totaled just $100.
    • Net loss to common stockholders of $57.4 million, an increase of $24.9 million compared to a net loss of $32.5 million in 2024. This increased net loss to common stockholders reflects the above noted one-time expenses in the quarter along with $12.9 million of tax expense recognized in Q1 2026 against no tax provision for the comparable quarter in 2025.
      • Excluding the $19.3 million non-cash stock-based compensation, the non-GAAP adjusted net loss to common stockholders was $38.1 million in the quarter.
    • In May 2026, the Company declared a $9.0 million dividend to be paid on or about May 29, 2026, to shareholders of record on May 15, 2026, continuing the Company's continued commitment to reward its shareholder base.
    • As of March 31, 2026, the Company's liquid assets (defined as: "cash, marketable securities, securities owned and receivable from clearing brokers") totaled $67.4 million at the end of Q1 2026, working capital totaled $21.9 million, total assets were $85.3 million and total stockholders' equity was $31.6 million.

     

    DOMINARI HOLDINGS INC.

    Condensed Consolidated Balance Sheets

    ($ in thousands except share and per share amounts)



















    March 31,





    December 31,







    2026





    2025







    (Unaudited)









    ASSETS













    Cash and cash equivalents



    $

    27,477





    $

    34,005



    Marketable securities





    6,901







    46,516



    Securities owned





    11,118







    9,756



    Receivable from clearing brokers





    21,883







    3,995



    Long-term equity investments





    11,846







    11,744



    Loans to employees





    1,669







    1,767



    Right-of-use assets





    2,586







    2,721



    Prepaid expenses and other assets





    1,840







    2,403



    Total assets



    $

    85,320





    $

    112,907





















    LIABILITIES AND STOCKHOLDERS' EQUITY

















    Accounts payable and accrued expenses



    $

    777





    $

    611



    Accrued compensation and commissions





    25,005







    17,754



    Accrued dividends payable





    364







    10,335



    Contract liabilities





    4,679







    4,504



    Lease liability





    2,744







    2,841



    Income taxes payable





    20,174







    7,318



    Other liabilities





    -







    173



    Total liabilities





    53,743







    43,536





















    Stockholders' equity

















    Preferred stock, $.0001 par value, 50,000,000 authorized

















    Convertible Preferred Series D: 5,000,000 shares designated; 3,825 shares issued 

      and outstanding as of March 31, 2026 and December 31, 2025; liquidation value of

      $0.0001 per share





    -







    -



    Convertible Preferred Series D-1: 5,000,000 shares designated; 834 shares issued and 

       outstanding as of March 31, 2026 and December 31, 2025; liquidation value of

       $0.0001 per share





    -







    -



    Common stock, $0.0001 par value, 100,000,000 shares authorized; 22,613,781 and 

       16,067,435 shares issued as of March 31, 2026, and December 31, 2025,

       respectively; 22,613,781 and 16,067,435 shares outstanding as of March 31, 2026

       and December 31, 2025, respectively





    2







    -



    Additional paid-in capital





    357,099







    337,505



    Accumulated deficit





    (325,492)







    (268,134)



    Total Dominari stockholders' equity





    31,609







    69,371



    Non-controlling interests





    (32)







    -



    Total stockholders' equity





    31,577







    69,371



    Total liabilities and stockholders' equity



    $

    85,320





    $

    112,907



     

    DOMINARI HOLDINGS INC.

    Condensed Consolidated Statements of Operations

    ($ in thousands except share and per share amounts)

    (Unaudited)













    Three Months Ended







    March 31,







    2026





    2025



    Revenues













    Underwriting services



    $

    32,949





    $

    5,606



    Carried interest





    1,096







    -



    Commissions





    2,490







    2,190



    Interest income





    308







    39



    Principal transactions





    (1,532)







    (910)



    Other revenue





    494







    315



    Total revenue





    35,805







    7,240





















    Operating costs and expenses

















    Compensation and benefits





    68,159







    15,457



    Advisory fees





    36







    20,944



    Legal fees





    1,485







    704



    Professional and consulting fees





    876







    829



    Other expenses





    2,871







    2,188



    Total operating expenses





    73,427







    40,122



    Loss from operations





    (37,622)







    (32,882)





















    Other income (expenses)

















    Other income





    108







    -



    Interest income





    61







    21



    Gain (loss) on marketable securities, net





    (7,014)







    (168)



    Realized and unrealized gain loss on notes receivable, net





    -







    221



    Change in carrying value of investments





    -







    320



    Total other income (expenses)





    (6,845)







    394



    Net loss before income tax expense



    $

    (44,467)





    $

    (32,488)



    Provision for income taxes





    12,868







    -



    Net loss





    (57,335)







    (32,488)



    Less: Net income attributable to non-controlling interests





    23







    -



    Net loss attributable to common stockholders of Dominari Holdings Inc.



    $

    (57,358)





    $

    (32,488)





















    Net loss per share, basic and diluted

















    Basic and Diluted



    $

    (3.17)





    $

    (3.02)





















    Weighted average number of shares outstanding, basic and diluted

















    Basic and Diluted





    18,068,269







    10,775,219



     

    DOMINARI HOLDINGS INC.

    Condensed Consolidated Statements of Cash Flows

    ($ in thousands)

    (Unaudited)













    Three Months Ended







    March 31,







    2026





    2025



    Cash flows from operating activities













    Net loss



    $

    (57,335)





    $

    (32,488)



    Adjustments to reconcile net loss to net cash used in operating activities:

















    Amortization of right-of-use assets





    135







    52



    Depreciation





    26







    26



    Change in carrying value of long-term investment





    -







    (320)



    Non-cash underwriting revenues





    (10,080)







    (697)



    Non-cash commission expense





    7,610







    -



    Stock-based compensation – employees





    19,243







    28,626



    Stock-based compensation – advisors





    36







    -



    Realized (gain) loss on securities owned





    (590)







    714



    Unrealized loss on securities owned





    2,122







    259



    Realized loss on marketable securities





    6,949







    670



    Unrealized (gain) loss on marketable securities





    115







    (468)



    Realized and unrealized (gain) loss on note receivable





    -







    (221)



    Changes in operating assets and liabilities:

















    Prepaid expenses and other assets





    537







    (2,401)



    Receivable from clearing brokers





    (17,888)







    4,848



    Accounts payable and accrued expenses





    165







    520



    Accrued compensation and commissions





    7,251







    1,210



    Right of use asset and liability, net





    (97)







    (122)



    Contract liabilities





    175







    632



    Income taxes payable





    12,856







    -



    Other liabilities





    (173)







    395



    Net cash (used in) provided by operating activities





    (28,942)







    1,235





















    Cash flows from investing activities

















    Purchase of marketable securities





    (9,185)







    (9,035)



    Sale of marketable securities





    41,736







    1,776



    Purchase of securities owned





    (1,666)











    Sale of securities owned





    1,242







    -



    Purchase of long-term investments





    (102)







    -



    Redemption of long-term investments





    -







    538



    Collection of principal on note receivable













    1,143



    Collection of loans to employees





    98







    142



    Net cash provided by (used in) investing activities





    32,123







    (5,436)





















    Cash flows from financing activities

















    Cash paid for dividends





    (9,971)







    (7,080)



    Distributions to non-controlling interest





    (55)







    -



    Cash from issuance common stock, net of offering cost





    -







    13,517



    Cash from issuance common stock for exercised warrants





    317







    -



    Net cash (used in) provided by financing activities





    (9,709)







    6,437





















    Net increase in cash and cash equivalents





    (6,528)







    2,236



    Cash and cash equivalents, beginning of period





    34,005







    4,079



    Cash and cash equivalents, end of period



    $

    27,477





    $

    6,315





















    Cash paid for interest and taxes



    $

    17





    $

    -



    The press release contains non-GAAP financial measures within the meaning of Regulation G promulgated by the Securities and Exchange Commission. To supplement its consolidated condensed financial statements presented in accordance with U.S. generally accepted accounting principles (GAAP), the Company provides the additional non-GAAP financial measures of operating income, net income and earnings per share. The Company believes that these non GAAP financial measures are appropriate to enhance understanding of its past performance as well as prospects for future performance. A reconciliation of the differences between these non GAAP financial measures with the most directly comparable financial measure calculated in accordance with GAAP is shown in the table below.

     





    Three Months

    Ended





    Three Months

    Ended







    March 31,

    2026





    March 31,

    2025



    Loss from operations



    $

    (37,622)





    $

    (32,882)



    Non-cash stock-based compensation





    19,279







    28,626



    Adjusted loss from operations



    $

    (18,343)





    $

    (4,256)





















    Net loss attributable to common stockholders' of Dominari Holdings



    $

    (57,358)





    $

    (32,488)



    Non-cash stock-based compensation





    19,279







    28,626



    Adjusted net loss before income tax expense



    $

    (38,079)





    $

    (3,862)



    Adjustment to the provision for income taxes





    -







    4,427



    Adjusted net loss to common stockholders' of Dominari Holdings





    (38,079)







    (8,289)



    Adjusted net loss per share, basic



    $

    (2.11)





    $

    (0.77)



    Weighted average number of shares outstanding, basic





    18,068,269







    10,775,219



    For additional information about Dominari Holdings Inc., please visit: https://www.dominariholdings.com/

    About Dominari Holdings Inc.

    The Company is a holding company that, through its various subsidiaries, is currently engaged in wealth management, investment banking, sales and trading and asset management. In addition to capital investment, Dominari provides management support to the executive teams of its subsidiaries, helping them to operate efficiently and reduce cost under a streamlined infrastructure. In addition to organic growth, the Company seeks opportunities outside of its current business to enhance shareholder value, including in the AI and Data Center sectors.

    Dominari Securities LLC's Mission Statement:

    Dominari Securities LLC, a principal subsidiary of Dominari Holdings Inc., is a dynamic, forward-thinking financial services company that seeks to create wealth for all stakeholders by capitalizing on emerging trends in the financial services sector and identifying early-stage future opportunities that are expected to generate a high rate of return for investors.

    Securities Brokerage and Registered Investment Adviser Services are offered through Dominari Securities LLC, a Member of FINRA, MSRB and SIPC. Securities brokerage, investment adviser and other non-bank deposit investments are not FDIC insured and may lose some or all of the principal invested. You can check the background of Dominari Securities LLC and its registered investment professionals and review its SEC Form CRS on FINRA's BrokerCheck site at https://brokercheck.finra.org. Information for Dominari Securities LLC and its registered investment professionals as well as its SEC Form CRS may also be found on FINRA's BrokerCheck site.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the SEC, which include but are not limited to the Risk Factors set forth in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025 relating to its business. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

    Contacts:

    Dominari Holdings Inc.

    https://www.dominariholdings.com/

    info@dominari.com 

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/dominari-q1-revenue-increases-by-395-over-q1-2025-302770568.html

    SOURCE Dominari Holdings Inc.

    Get the next $DOMH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DOMH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DOMH
    SEC Filings

    View All

    Dominari Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Dominari Holdings Inc. (0000012239) (Filer)

    5/27/26 5:00:42 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Dominari Holdings Inc.

    10-Q - Dominari Holdings Inc. (0000012239) (Filer)

    5/12/26 9:42:51 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dominari Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Dominari Holdings Inc. (0000012239) (Filer)

    3/31/26 9:20:25 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOMH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Ledwick Tim S

    4 - Dominari Holdings Inc. (0000012239) (Issuer)

    3/25/26 8:10:56 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Hayes Anthony

    4 - Dominari Holdings Inc. (0000012239) (Issuer)

    3/24/26 9:23:32 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Haug Kyle

    4 - Dominari Holdings Inc. (0000012239) (Issuer)

    3/24/26 9:23:14 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOMH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: CEO Hayes Anthony bought $89,054 worth of shares (23,000 units at $3.87), increasing direct ownership by 1% to 1,750,873 units (SEC Form 4)

    4/A - Dominari Holdings Inc. (0000012239) (Issuer)

    12/10/25 9:22:01 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: President Wool Kyle Michael bought $96,798 worth of shares (25,000 units at $3.87), increasing direct ownership by 2% to 1,211,828 units (SEC Form 4)

    4/A - Dominari Holdings Inc. (0000012239) (Issuer)

    12/10/25 9:20:35 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President Wool Kyle Michael decreased direct ownership by 1% to 2,453,817 units (SEC Form 4)

    4 - Dominari Holdings Inc. (0000012239) (Issuer)

    12/10/25 7:54:17 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOMH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The Rise of the American Drone Industry

    NEW YORK, June 2, 2026 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) today issued the following letter to shareholders: Dear Shareholder,The rise of drones in our society has become ubiquitous. Whether it's the discussion of their use to make deliveries, their use to cover sporting events, or their constant presence when discussing conflicts in the middle east, drones are everywhere. And at Dominari, we are proud to play our part in building and supporting this growing American industry.Since our inception, Dominari has been involved in supporting this important new facet

    6/2/26 8:00:00 AM ET
    $DOMH
    $JFB
    $UMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    General Bldg Contractors - Nonresidential Bldgs
    Consumer Discretionary

    Dominari Holdings Congratulates Cerebras Systems on "Blockbuster" Initial Public Offering

    Shares Skyrocket in Debut as AI Mania Grips Wall Street According to ReutersNEW YORK, May 15, 2026 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) ("Dominari" or the "Company") congratulates Cerebras Systems (NASDAQ:CBRS), on its Initital Public Offering, which has been called a "Blockbuster Debut" as the next hot AI stock, by Investor's Business Daily. On May 14, 2026, Cerebras stock opened at $185.00 and closed $126 higher at $311.07 per share, an approximate 68% increase on its first day of trading. Dominari Securities' SPV 1 & 2 invested early in Cerebras, at $39.00 per

    5/15/26 8:00:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dominari Holdings Issues Shareholder Letter

    Company Reports Revenue of $35.8 million up 395% from prior yearTotal Capital invested across all SPV Series: approximately $292 millionRecord Date of May 15th for $9 Million Dividend PaymentNEW YORK, May 13, 2026 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) ("Dominari" or the "Company") today issued the following letter to shareholders: Dear Shareholder,As we approach mid-year, I want to take this opportunity to thank you for being a Dominari shareholder and provide you with some updates.10Q SummaryThe year is off to a strong start. As noted in our 10Q just filed with t

    5/13/26 8:00:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOMH
    Leadership Updates

    Live Leadership Updates

    View All

    Dominari Expands Strategic Leadership with Appointment of Ambassador Jamie McCourt to Advisory Board

    Dominari Withdraws $2 Billion Shelf Registration NEW YORK, Dec. 8, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) today announced a major enhancement to its strategic leadership with the appointment of Ambassador Jamie McCourt to the Advisory Board of Dominari Securities. Separately, the company has formally withdrawn its previously filed $2 billion shelf registration statement, reflecting confidence in its financial position and growth outlook. Globally recognized diplomat, executive and entrepreneur Ambassador Jamie McCourt Joins Advisory Board Ambassador McCourt

    12/8/25 8:30:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dominari Securities Receives Approval as a Limited Underwriting Member of the New York Stock Exchange

    Enables direct participation in underwriting activities conducted through NYSE and NYSEAmerican platforms NEW YORK, Oct. 9, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) ("Dominari" or the "Company") today announced that its wholly owned subsidiary, Dominari Securities LLC, has been approved as a Limited Underwriting member of the New York Stock Exchange and NYSE American Equities (the "Exchanges") effective October 8, 2025. This approval marks an important regulatory milestone for Dominari Securities as it continues to expand its capabilities within U.S. capital m

    10/9/25 8:00:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dominari Securities Appoints Communications and Growth Strategist Brian Parsley to Board

    Accomplished entrepreneur and global speaker to strengthen firm's marketing, investor engagement and strategic communications to help drive growth NEW YORK, Sept. 10, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH), today announced the appointment of Brian Parsley to its Board of Directors. Parsley, an accomplished entrepreneur, behavioral analyst and internationally recognized speaker, will support the firm's growth by enhancing its marketing, investor outreach and overall communications strategy. Mr. Parsley has more than 30 years of experience in entrepreneurship,

    9/10/25 8:30:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOMH
    Financials

    Live finance-specific insights

    View All

    Dominari Holdings Issues Shareholder Letter

    Company Reports Revenue of $35.8 million up 395% from prior yearTotal Capital invested across all SPV Series: approximately $292 millionRecord Date of May 15th for $9 Million Dividend PaymentNEW YORK, May 13, 2026 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) ("Dominari" or the "Company") today issued the following letter to shareholders: Dear Shareholder,As we approach mid-year, I want to take this opportunity to thank you for being a Dominari shareholder and provide you with some updates.10Q SummaryThe year is off to a strong start. As noted in our 10Q just filed with t

    5/13/26 8:00:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dominari Q1 Revenue Increases by 395% Over Q1 2025

    Underwriting revenues increased over five-fold NEW YORK, May 13, 2026 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) ("Dominari" or the "Company"), today announced highlights of its financial results for the quarter ended March 31, 2026, which were filed with the Securities and Exchange Commission ("SEC") in the Company's quarterly SEC Form 10Q. The Company stated that:  "In  the first quarter of 2026,  we experienced continued revenue growth mainly from underwriting services, increased our annual recurring revenue from our management fees that we earn on deals that we bri

    5/13/26 7:00:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dominari Holdings Announces Record Date for Cash Dividend

    NEW YORK, May 4, 2026 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) is pleased to announce that its board of directors has authorized a special cash dividend of, in the aggregate, approximately $9 million, or approximately $0.31 per share. The dividend is payable on or about May 29, 2026, to DOMH's common stock shareholders and certain DOMH warrant holders (on an as-exercised basis) of record as of the close of business on May 15, 2025. For additional information about Dominari Holdings Inc., please visit: https://www.dominariholdings.com/About Dominari Holdings Inc.The C

    5/4/26 8:00:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOMH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Dominari Holdings Inc.

    SC 13D/A - Dominari Holdings Inc. (0000012239) (Subject)

    6/13/24 8:56:04 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Dominari Holdings Inc.

    SC 13D/A - Dominari Holdings Inc. (0000012239) (Subject)

    6/13/24 4:32:07 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care